KF
PACB icon

Krilogy Financial’s Pacific Biosciences PACB Stock Holding History

Krilogy Financial’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25K Buy
+15,344
New +$27.4K ﹤0.01% 965

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Krilogy Financial's PACB Position: Q1 2026 in Review

Krilogy Financial opened a new position in Pacific Biosciences (PACB) in Q1 2026: 15,344 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #965 among its holdings.

229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Krilogy Financial held 15,344 shares of Pacific Biosciences worth $25K as of Q1 2026.
  • Pacific Biosciences was a new Krilogy Financial position in Q1 2026.
  • Pacific Biosciences made up ﹤0.01% of Krilogy Financial's portfolio in Q1 2026, its #965 holding.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Krilogy Financial's 13F filing for Q1 2026, filed 17 Apr 2026.